Basal Cell Carcinoma News and Research

RSS
Basal cell cancer begins in the lowest layer of the epidermis, the basal cell layer. About 8 out of 10 skin cancers are basal cell carcinomas. They usually begin on areas exposed to the sun, such as the head and neck. Basal cell carcinoma was once found mostly in middle-aged or older people. But now it is also being seen in younger people. This may be because people are spending more time in the sun without protecting their skin.

Basal cell carcinoma tends to grow slowly. It is very rare for a basal cell cancer to spread to distant parts of the body (metastasize). But if it is not treated, it can grow into nearby areas and spread into the bone or other tissues beneath the skin.

After treatment, basal cell carcinoma can come back (recur) in the same place on the skin. New basal cell cancers can also start in other places on the skin. As many as half of the people who have one basal cell cancer will get a new skin cancer within 5 years.
MorphoSys inks manufacturing agreement with Boehringer Ingelheim

MorphoSys inks manufacturing agreement with Boehringer Ingelheim

Infinity commences IPI-926 Phase 2 clinical trial in rare, life-threatening bone cancer

Infinity commences IPI-926 Phase 2 clinical trial in rare, life-threatening bone cancer

Night shift work may reduce risk of skin cancer in women

Night shift work may reduce risk of skin cancer in women

Cannabis Science extract treatments help kill cancer cells

Cannabis Science extract treatments help kill cancer cells

Infinity commences IPI-926 Phase 2 trial in patients with pancreatic cancer

Infinity commences IPI-926 Phase 2 trial in patients with pancreatic cancer

Study: Active wound healing can lead to increased risk of basal cell carcinoma in skin

Study: Active wound healing can lead to increased risk of basal cell carcinoma in skin

Ultraviolet light activates enzyme that helps skin cancer cells survive, proliferate: Researchers

Ultraviolet light activates enzyme that helps skin cancer cells survive, proliferate: Researchers

Provectus reports progress in PV-10 program for metastatic melanoma

Provectus reports progress in PV-10 program for metastatic melanoma

Infinity announces enrollment in IPI-926 Phase 1b/2 clinical trial for pancreatic cancer

Infinity announces enrollment in IPI-926 Phase 1b/2 clinical trial for pancreatic cancer

Infinity announces Phase 1b/2 clinical trial of IPI-926 in patients with metastatic pancreatic cancer

Infinity announces Phase 1b/2 clinical trial of IPI-926 in patients with metastatic pancreatic cancer

Perrigo first quarter revenue increases 21% to record $641 million

Perrigo first quarter revenue increases 21% to record $641 million

New annual campaign to prevent skin cancer

New annual campaign to prevent skin cancer

Many skin cancer patients unaware of being diagnosed with melanoma or nonmelanoma cancer

Many skin cancer patients unaware of being diagnosed with melanoma or nonmelanoma cancer

New LED device may help advance photodynamic therapy for skin cancer

New LED device may help advance photodynamic therapy for skin cancer

COU-AA-301 Phase 3 study demonstrates improvement in CRPC survival rate

COU-AA-301 Phase 3 study demonstrates improvement in CRPC survival rate

Genentech initiates GDC-0449 Phase II clinical trial in BCC patients

Genentech initiates GDC-0449 Phase II clinical trial in BCC patients

Infinity announces preliminary results of IPI-926 Phase 1 study in patients with solid tumors

Infinity announces preliminary results of IPI-926 Phase 1 study in patients with solid tumors

Loss of INPP5A gene can predict cutaneous squamous cell carcinoma progression

Loss of INPP5A gene can predict cutaneous squamous cell carcinoma progression

Perrigo receives FDA approval to manufacture, market Imiquimod Cream, 5%

Perrigo receives FDA approval to manufacture, market Imiquimod Cream, 5%

Curis announces preliminary results of GDC-0449 Phase II clinical trial in advanced ovarian cancer

Curis announces preliminary results of GDC-0449 Phase II clinical trial in advanced ovarian cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.